Please select the outcome measures that correspond to the clinical trial below.
Title: A Primary-school-based Study to Reduce Prevalence of Childhood Obesity in Terres de l'Ebre (Catalunya (Spain) - EDAL-Educació en Estils Saludables de Vida alimentació-2: Study Protocol for a Randomized Controlled Trial
Brief Summary: Our hypothesis is that a regular systematic educational intervention in primary school improves lifestyle choices and reduces obesity. As such, the aim of the study is to evaluate the effects of a 3-year school-based program of lifestyle improvement, including diet and physical activity, implemented by university students acting as "health promoting agents" (HPA) on the prevalence of obesity.


Options:
A: Body height and weight (Sept 2006- May 2009); Healthy Start Knowledge Quiz (Sept 2006- May 2009); 24-hour diet observation and recall (Sept 2006- May 2009); Physical activity (Sept 2006- May 2009); Television viewing (child outcomes, measured immediately after the study and at a 1-year follow-up visit) (Sept 2006- May 2009); Score on short Acculturation Scale (parent outcome, measured immediately after the study and at a 1-year follow-up visit) (Sept 2006- May 2009); Nutrition and exercise knowledge (Sept 2006- May 2009); Self-efficacy for eating and exercise behaviors (Sept 2006- May 2009); Score on Nutrition Attitudes Scale (Sept 2006- May 2009); Support and role modeling for healthy eating (teacher outcomes, measured immediately after the study and at a 1-year follow-up visit) (Sept 2006- May 2009)
B: Mean Change From Baseline In Body Mass Index At 12 Weeks (Up to 12 weeks); Mean Change From Baseline In Fasting Glucose Profile At 12 Weeks (Up to 12 weeks); Mean Change From Baseline In Fasting Glycated Haemoglobin At 12 Weeks (Up to 12 weeks); Mean Change From Baseline In Fasting Triglycerides At 12 Weeks (Up to 12 weeks); Mean Change From Baseline In Fasting Total Cholesterol At 12 Weeks (Up to 12 weeks); Mean Change From Baseline In Fasting High Density Lipoprotein Cholesterol At 12 Weeks (Up to 12 weeks); Mean Change From Baseline In Fasting Low Density Lipoproteins Cholesterol At 12 Weeks (Up to 12 weeks); Mean Change From Baseline In Fasting Creatinine At 12 Weeks (Up to 12 weeks); Mean Change From Baseline In Fasting Urea At 12 Weeks (Up to 12 weeks); Mean Change From Baseline In Fasting Urea Nitrogen At 12 Weeks (Up to 12 weeks); Mean Change From Baseline In Fasting Uric Acid At 12 Weeks (Up to 12 weeks); Mean Change From Baseline In Fasting Glutamic Oxalacetic Transaminase At 12 Weeks. (Up to 12 weeks); Mean Change From Baseline In Fasting Glutamic Pyruvic Transaminase, At 12 Weeks (Up to 12 weeks); Mean Change From Baseline In Fasting Bilirubin Profile, At 12 Weeks (Up to 12 weeks); Mean Change From Baseline In Indirect Of Maximum Oxygen Consumption At 12 Weeks (Up to 12 weeks); Mean Change From Baseline In Speed At 12 Weeks (Up to 12 weeks); Mean Change From Baseline In Strength-Resistance At 12 Weeks (Up to 12 weeks); Mean Change From Baseline In Power At 12 Weeks (Up to 12 weeks)
C: Reduction in prevalence of obesity (Changes from baseline in prevalence of obesity at 3 academic years)
D: Change from baseline in physical activity as assessed by Actigraph accelerometer (Baseline, 6 months and 1 year)

Answer: C